Codosiran (QPI-1007) inhibits the loss of retinal ganglion cells (RGCs) and prevents optic neuropathy by targeting Caspase-2 (CASP2), which is highly expressed in RGCs during optical injury. This evidence concerns the gene CASP2 and Optic neuropathy.